@CheriJacobus@grantstern@AdamKinzinger THIS^^ ffs…
I was lucky enough to go to West Point so I graduated w/o loans- but I grew up poor/blue-collar. Hell, most of my family didn’t even have collars much less blue ones. Had I needed to figure out a 4yr ed on my own? Loans.
You’re welcome.
Next dumb question?
@HunterBiden@antifaoperative Bruh… why weren’t you an advisor for your Dad????
You’re spot on but could have used this breath of fresh air a hot minute ago🥴
@IovanceBio Not even “our exciting work”? Marketing needs to have a fireside chat with someone - a very close up and personal one.
Come on, guys… you can do better than this…
@BIOTECHSCANNER Contrary to your statement, I actually have a decent amount of skin in the IOVA game = I have a vested interest in the success here.
But I’m also not emotionally wedded to the stock so will continue to point out some of the things I see as weaknesses in management’s performance.
@BIOTECHSCANNER I stand corrected. It is actually 1 pt per quarter, not per month, at each ATC.
My point is that talking about total addressable market is beyond premature when they can’t even address a small portion of the current market they are approved in.
@BIOTECHSCANNER I am aware of that info. However, right now, they are treating approx 1 pt/mo per ATC. With around 90 ATC’s, they aren’t anywhere near capacity. There’s a real disconnect here.
@BIOTECHSCANNER Indications are great and thus hold a tremendous amount of potential. However, they are barely touching melanoma pts as it is. One pt per ATC/mo is barely any volume, even in the melanoma sphere. If they can’t scale to meet the need of additional indications, what’s the point?
@BIOTECHSCANNER I don’t know how the FDA approves this after what they outlined as issues in the CRL. Nothing has changed in the REPL submission/trial data and certainly not in their trial format…